M&T Bank Corp Has $113.78 Million Stock Holdings in Danaher Co. (NYSE:DHR)

M&T Bank Corp cut its stake in Danaher Co. (NYSE:DHR - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 495,675 shares of the conglomerate's stock after selling 7,822 shares during the period. M&T Bank Corp owned about 0.07% of Danaher worth $113,782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Heck Capital Advisors LLC bought a new position in shares of Danaher during the fourth quarter valued at $27,000. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher during the 4th quarter worth about $31,000. Golden State Wealth Management LLC acquired a new position in Danaher in the fourth quarter valued at about $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher during the fourth quarter worth about $31,000. Finally, Pineridge Advisors LLC increased its holdings in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock worth $34,000 after buying an additional 57 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Stock Up 2.5 %

DHR traded up $5.06 during trading hours on Wednesday, hitting $210.97. 5,137,044 shares of the company's stock were exchanged, compared to its average volume of 4,588,315. The stock's 50-day moving average is $223.22 and its two-hundred day moving average is $243.63. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The stock has a market cap of $150.78 billion, a price-to-earnings ratio of 39.96, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a boost from Danaher's previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher's dividend payout ratio (DPR) is presently 24.24%.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Robert W. Baird decreased their price target on Danaher from $277.00 to $268.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 28th. Royal Bank of Canada restated an "outperform" rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Bank of America upgraded shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Citigroup dropped their price objective on shares of Danaher from $285.00 to $265.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group set a $250.00 price target on shares of Danaher in a research report on Wednesday, January 15th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.